COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pain and Chronic Pancreatitis - Clinical End Experimental Studies (CPP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00755573
Recruitment Status : Completed
First Posted : September 19, 2008
Last Update Posted : August 20, 2010
Radboud University
Information provided by:
Aalborg University Hospital

Brief Summary:
The aim of the study is to investigate the effect of pregabalin in pain resulting from chronic pancreatitis. The effect will be investigated by means of questionnaires concerning the daily experience of pain and the general quality of life. Furthermore the patients will be invited to participate in experimental testing with a multimodal pain model. The experimental testing will include stimulation of the skin, muscle and visceral tissue. The results from the experimental part of the study may help us to understand the mechanisms of action of pregabalin in this patient population.

Condition or disease Intervention/treatment Phase
Chronic Pancreatitis Drug: Pregabalin Drug: placebo Phase 2 Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical and Experimental Pilot Study of Pregabalin in Patients With Chronic Pancreatitis
Study Start Date : October 2008
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis
Drug Information available for: Pregabalin

Arm Intervention/treatment
Active Comparator: Pregabalin
Pregabalin 300 mg - 600 mg BID
Drug: Pregabalin
Pregabalin 300 mg - 600 mg BID
Other Name: Lyrica

Placebo Comparator: Placebo
Placebo arm
Drug: placebo
Regime as described for pregabalin
Other Name: Inactive comparator (placebo)

Primary Outcome Measures :
  1. Patient pain diary based on the VAS score and different questionaries [ Time Frame: Pain diary treatmentday -7 to +21. Questionaries are adressed 7 days prior to study medication and on day 21 during the study medication period ]
    The primary efficacy parameter to be evaluated is pain relief assessed using a patient pain diary based on the visual analog scale (VAS). Furthermore different questionnaires, including the modified brief pain inventory-short form (mBPI-sf), the painDETECT questionnaire (PD-Q) and patient global impression of change (PGIC)will be used to explore further aspects of pain character and influence on cognitive and affective components.

Secondary Outcome Measures :
  1. Questionary addressing quality of life [ Time Frame: Questionaries are adressed 7 days prior to study medication and on day 21 during the study medication period ]
    Secondary efficacy parameters are changes in quality of life compared to baseline level. The European Organization for research and treatment of cancer quality of life questionnaire (EORTC QOL-C30).Also the tolerability of the drug in this patient population will be compared to placebo.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients between the ages of 18 and 75 years with a diagnosis of chronic pancreatitis diagnosed using the Mayo Clinic Diagnostic criteria criteria ((Layer P, Gastroenterology 1994;107:1481-1487]). Both diabetic and non-diabetic patients will be allowed to enter the study.
  2. The patients must suffer from chronic abdominal pain typical for pancreatitis, meet the criteria for chronic pain (pain ≥ 3 days per week in at least 3 months) and must consider their pain as severe enough for medical treatment.
  3. Personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
  4. Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other trial procedures.

Exclusion Criteria:

  1. Patients with evidence or history of medical or surgical disease of importance for this study as judged by investigator
  2. Presence or history of major depression
  3. Patients with previously diagnosed moderate to severe renal impairment. Patients with creatinine values > 2x ULN and/or with a significant change to their normal values should be excluded.
  4. Patients with a screening 12-lead ECG demonstrating any of the following: heart rate >100 bpm, QRS duration >120 msec, QTc interval >450 msec, PR interval >210 msec, any clinically significant rhythm abnormality, any evidence of myocardial ischemia or injury.
  5. Patients with any clinically significant laboratory abnormalities that in the opinion of the investigator may increase the risk associated with trial participation or may interfere with the interpretation of the trial results.
  6. Patients treated with pregabalin (Lyrica®) during the previous 4 months.
  7. Treatment with an investigational drug within 4 months preceding the first dose of study medication of importance for this study as judged by investigator.
  8. Female patients who are pregnant or lactating, or intend to become pregnant. Male patients who intend to father a child during the course of the study. A pregnancy test will be conducted at visit 1 and 3 to ensure that female patients are not pregnant during the study period. The investigator will have to ensure that fertile female patients use a safe contraception method during the study and for at least 35 hours after termination of the study period. The following methods are considered as safe contraception methods:

    • The pill
    • IUD
    • Gestagen Injection
    • Subdermal Implantation (Implanon)
    • Hormone vaginal ring
    • Transdermal Plaster
  9. Patients unwilling or unable to comply with the lifestyle guidelines.
  10. Patients must not suffer from generalized painful conditions other than chronic pancreatitis; however patients with localized painful disorders will be allowed to enter the study
  11. Clinical significant illness within two weeks of participating in this study.
  12. Involved in planning or conducting the study.
  13. Hypersensitivity to pregabalin or any of its components.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00755573

Layout table for location information
Department of Gastroenterology, Aalborg Hospital
Aalborg, Denmark, 9000
Department of Suregery, Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500
Sponsors and Collaborators
Aalborg University Hospital
Radboud University
Layout table for investigator information
Principal Investigator: Asbjørn M Drewes, MD, PhD Dapartment og Gastroenterology, Aalborg Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Asbjørn Drewes Professor, Department of Gastroenterology, Aalborg Hospital Identifier: NCT00755573    
Other Study ID Numbers: A0081172/8967
First Posted: September 19, 2008    Key Record Dates
Last Update Posted: August 20, 2010
Last Verified: July 2009
Keywords provided by Aalborg University Hospital:
Neuropathic pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis, Chronic
Pancreatic Diseases
Digestive System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs